Camps P[au] - Search Results

Year	Number of Results
1991	1
1996	1
1998	1
1999	1
2000	3
2001	4
2002	2
2003	4
2004	2
2005	4
2006	6
2007	1
2008	5
2009	4
2010	6
2011	2
2012	5
2013	3
2014	1
2015	3
2016	1
2017	3
2018	3
2021	1
2022	0

1

Behavioural effects of novel multitarget anticholinesterasic derivatives in Alzheimer's disease.

Giménez-Llort L, Ratia M, Pérez B, Camps P, Muñoz-Torrero D, Badia A, Clos MV. Giménez-Llort L, et al. Among authors: camps p. Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):124-131. doi: 10.1097/FBP.0000000000000292. Behav Pharmacol. 2017. PMID: 28125507 Review.

2

Dimeric and hybrid anti-Alzheimer drug candidates.

Muñoz-Torrero D, Camps P. Muñoz-Torrero D, et al. Among authors: camps p. Curr Med Chem. 2006;13(4):399-422. doi: 10.2174/092986706775527974. Curr Med Chem. 2006. PMID: 16475930 Review.

3

Generation and Reactions of an Octacyclic Hindered Pyramidalized Alkene.

Camps P, Lozano D, Barbaraci C, Font-Bardia M, Luque FJ, Estarellas C. Camps P, et al. J Org Chem. 2018 May 18;83(10):5420-5430. doi: 10.1021/acs.joc.8b00212. Epub 2018 Apr 27. J Org Chem. 2018. PMID: 29652147

4

Cholinergic drugs in pharmacotherapy of Alzheimer's disease.

Camps P, Muñoz-Torrero D. Camps P, et al. Mini Rev Med Chem. 2002 Feb;2(1):11-25. doi: 10.2174/1389557023406638. Mini Rev Med Chem. 2002. PMID: 12369954 Review.

5

Clock/Sleep-Dependent Learning and Memory in Male 3xTg-AD Mice at Advanced Disease Stages and Extrinsic Effects of Huprine X and the Novel Multitarget Agent AVCRI104P3.

Giménez-Llort L, Santana-Santana M, Ratia M, Pérez B, Camps P, Muñoz-Torrero D, Badia A, Clos MV. Giménez-Llort L, et al. Among authors: camps p. Brain Sci. 2021 Mar 26;11(4):426. doi: 10.3390/brainsci11040426. Brain Sci. 2021. PMID: 33810622 Free PMC article.

6

Tacrine-huperzine A hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease.

Camps P, Muñoz-Torrero D. Camps P, et al. Mini Rev Med Chem. 2001 Jul;1(2):163-74. doi: 10.2174/1389557013406972. Mini Rev Med Chem. 2001. PMID: 12369981 Review.

7

Huprine X Attenuates The Neurotoxicity Induced by Kainic Acid, Especially Brain Inflammation.

Relat J, Pérez B, Camps P, Muñoz-Torrero D, Badia A, Victòria Clos M. Relat J, et al. Among authors: camps p. Basic Clin Pharmacol Toxicol. 2018 Jan;122(1):94-103. doi: 10.1111/bcpt.12852. Epub 2017 Sep 19. Basic Clin Pharmacol Toxicol. 2018. PMID: 28724203 Free article.

8

Neuroprotective Effects of the Multitarget Agent AVCRI104P3 in Brain of Middle-Aged Mice.

Relat J, Come J, Perez B, Camps P, Muñoz-Torrero D, Badia A, Gimenez-Llort L, Clos MV. Relat J, et al. Among authors: camps p. Int J Mol Sci. 2018 Sep 4;19(9):2615. doi: 10.3390/ijms19092615. Int J Mol Sci. 2018. PMID: 30181440 Free PMC article.

9

Alternative Access to Functionalized 2,8-Ethanonoradamantane Derivatives.

Camps P, Gómez T, Otermin A, Font-Bardia M. Camps P, et al. Molecules. 2017 May 31;22(6):906. doi: 10.3390/molecules22060906. Molecules. 2017. PMID: 28561800 Free PMC article.

10

Huprines for Alzheimer's disease drug development.

Muñoz-Torrero D, Camps P. Muñoz-Torrero D, et al. Among authors: camps p. Expert Opin Drug Discov. 2008 Jan;3(1):65-81. doi: 10.1517/17460441.3.1.65. Expert Opin Drug Discov. 2008. PMID: 23480140

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results